Second-line chemotherapy in advanced biliary cancer: a systematic review. - Wikidata - awgldk - TriplyDB

Second-line chemotherapy in advanced biliary cancer: a systematic review.

Second-line chemotherapy in advanced biliary cancer: a systematic review.

http://www.wikidata.org/entity/Q38207456

about

Gemcitabine-based chemotherapy for advanced biliary tract carcinomas The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Current Status on Cholangiocarcinoma and Gallbladder Cancer Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.Long term responders to palliative chemotherapy for advanced biliary tract cancer.Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function Treatment of advanced Gall bladder cancer in the real world-can continuation chemotherapy improve outcomes?A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer Systemic Therapy of Cholangiocarcinoma.FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma Biliary tract cancers: SEOM clinical guidelines Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.New Horizons for Precision Medicine in Biliary Tract Cancers.Emerging molecular targets and therapy for cholangiocarcinoma.Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.Cholangiocellular Carcinoma.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review.Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.Repurposing itraconazole for the treatment of cancer.Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects.Therapie des metastasierten Cholangiokarzinoms The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers

P2860

Q24187573-00520873-EFB3-47FC-B2AD-111DB8B70F8B Q26751224-2477C901-7F9E-49DC-A9E1-B2A4CD42583B Q28077797-DBADBF12-F9FC-414E-9712-FE78B8CF6EFB Q31033443-B912AAA5-0095-44B2-851C-870DA90D96D4 Q33420378-C316396E-564D-42B1-B7E2-20F31D3BD4DE Q33428348-6CEB591B-B74E-4C44-A6CE-AE01CB71E504 Q33438718-C8C8E9DF-5500-4951-ACCB-A38B7AAABCEB Q33441341-5D2F9FE3-566C-4E0E-B50A-6570DD98624F Q33442862-B19B5040-0B6E-4F1C-8A0D-F9FA67CCA24E Q33593193-82584565-C65D-44DD-A199-21683554B2AA Q33593207-74829412-F735-4A76-A46D-40054D5AED77 Q33593225-F38D63A4-444C-4E94-B09F-B52339D4DD97 Q33738937-066FC561-BB8F-4849-AEFB-E35C8575D5DD Q34551877-1660B55D-59DF-4712-A796-B315D2952E28 Q35078039-E529A324-61F4-4363-B878-4043FFAB3B2E Q36400234-4F295B23-0834-471B-8B6A-F49AD420BFA0 Q37131675-E436CCFA-6762-4E50-9287-C09B590A5139 Q38619219-9D66A379-1420-4E75-8145-B631148DC715 Q38642455-939DEEEA-D04C-4D50-8F14-2D053500553B Q38673037-98D553BF-6D95-44C0-BE7B-7B48547F2DAD Q38701620-AE7EAB47-43BB-4CA3-8BEC-26AA1A77AA72 Q38746546-F863A5E0-A084-4A9B-8A1D-65EF17F56392 Q38812588-AFDE8598-5312-47DB-9F57-4C3CC67ADC05 Q39012507-332E97B9-8FA6-41A2-A1DB-97E416F85E24 Q39022553-27677CE6-A97F-42C5-A536-7E95EDF9EC2C Q40824695-92F02507-9F08-42C2-B67C-1F5BF87CEA6F Q40860251-4D908626-4583-4F6F-9301-01DE3CE844C7 Q41613808-D7F5BD32-BA54-496B-A13E-4895A0B87574 Q48126896-D9A4D5B7-0B1C-4EA9-8E9C-66AC62768D74 Q48333251-68FF294B-E703-45FC-BF31-28F9A50AB69A Q53579614-824D07F9-498D-407F-A937-4F3E08CEC074 Q55223567-84E32BA9-E99F-4E4D-8EF6-AEC3BBA9965E Q57074642-E894F588-BFF3-4C07-96D9-0A7B85EAF8AA Q58601441-378593E2-E9A8-49CE-B138-593E6DA32219

P2860

Second-line chemotherapy in advanced biliary cancer: a systematic review.

http://www.wikidata.org/entity/Q38207456

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Second-line chemotherapy in advanced biliary cancer: a systematic review.

@en

type

label

Second-line chemotherapy in advanced biliary cancer: a systematic review.

@en

prefLabel

Second-line chemotherapy in advanced biliary cancer: a systematic review.

@en

P1433

Q38207456-5DEED28E-DE5B-40AB-8AAD-989A2E34977C

P1476

Q38207456-E1D7F759-E9D0-4E98-9878-6DF56C470F87

P2093

Q38207456-2E932A19-654D-4B69-B8A0-1BA53ABF678A

Q38207456-6C19BD68-9FA2-4227-A91A-A66C33FCCC33

P2860

Q38207456-00162619-FB49-481D-8008-D865BCF2271A

Q38207456-039BBB1C-549F-4270-9364-BD9F8362EC21

Q38207456-0662B782-DC90-4B2E-8B7A-95F510A52344

Q38207456-12FA345B-C5D5-4611-B22A-379CA1E2A6ED

Q38207456-1781E59D-8D16-4062-AA3D-74DEB5C8C1AD

Q38207456-2125C178-2155-4843-BCE7-5F7C7E96E832

Q38207456-21A57E7B-9640-40D4-8B94-EC47332FAEA0

Q38207456-223D8C12-6762-4F6B-8A4E-F4AE04D7D854

Q38207456-2490B430-7984-4F1E-B083-043EF6435D62

Q38207456-3054549F-6CF9-43D9-98B3-E5CF1645CCE8

P304

Q38207456-3B3F10EA-85FF-4DC6-A677-31F2BF94479D

P31

Q38207456-F7676D8D-65F7-49C5-940A-9C8102B70365

P356

Q38207456-9F934136-618D-4D0F-B989-AD68D35E5DE1

P433

Q38207456-6187B910-FFF2-4AAA-9623-CE832AAA7DA4

P478

Q38207456-F1862475-DC05-432E-AF0E-AAA139E0CDCA

P50

Q38207456-04363856-C992-4515-915F-254087B1751E

Q38207456-AE341ED0-F1A5-4809-B6DD-E6FE3BDE5D6E

P577

Q38207456-0AD5DEA5-376F-44A5-BD57-FB971BBB6F6F

P5875

Q38207456-BDE0FC89-6BD2-4B20-BC8D-37220139E6F2

P698

Q38207456-F9D1548C-3E51-4DFD-ABAA-42E8FC09334A

P921

Q38207456-B21B8696-3358-47AB-87E3-CD06B9E8C850

P356

P1433

Annals of Oncology

P1476

Second-line chemotherapy in advanced biliary cancer: a systematic review.

@en

P2093

A Lamarca

http://www.w3.org/2001/XMLSchema#string

W David Ryder

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.

Cancer statistics, 2013

Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.

Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

S-1 monotherapy in patients with advanced biliary tract cancer.

Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

P304

2328-2338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU162

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Richard A Hubner

P577

2014-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261920855

http://www.w3.org/2001/XMLSchema#string

P698

24769639

http://www.w3.org/2001/XMLSchema#string

P921